Launch One Acquisition Corp. to combine with Minovia Therapeutics at $180M valuation, targeting Q4 2025 close

Launch One Acquisition Corp.

Minovia pre-money valuation of $180M; equity holders eligible for up to $57.5M earnout based on milestones.
Launch One trust holds ~$239.7M cash; at least $18M in PIPE investments and $5M bridge financing expected.
Lead product MNV-201 has FDA Fast Track and Rare Pediatric Disease designations; pivotal trial in preparation.
Transaction unanimously approved by both boards; expected to close Q4 2025 subject to shareholder approvals.
Combined company to be named Mito US One Ltd. and list on Nasdaq under new ticker.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.